Liposome targeting to tumors using vitamin and growth factor receptors

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Liposome-encapsulated anticancer drugs offer improved therapeutic efficacy and reduced toxicity by enhancing drug delivery to solid tumors.
• Ligand-targeted liposomes selectively increase the efficacy of carried agents against specific tumor cells expressing target receptors.
• Vitamin and growth factor receptors are attractive targets due to high expression in cancers and internalization upon ligand binding.

Purpose of the Study:

• To summarize strategies and advances in targeting liposomes to vitamin and growth factor receptors.
• To highlight the potential of ligand-targeted liposomes in cancer therapy.
• To focus on folate receptor and HER2/neu growth factor receptor targeting systems.

Main Methods:

• Review of in vitro and in vivo studies on liposome targeting strategies.
• Analysis of ligand-directed liposomal therapies utilizing natural ligands or synthetic agonists.
• Emphasis on systems targeting folate and HER2/neu receptors.

Main Results:

• Liposome technology enables targeted delivery of chemotherapeutic agents.
• Ligand-targeted liposomes demonstrate selective efficacy against receptor-bearing tumor cells.
• Folate receptor and HER2/neu receptor targeting show significant promise in preclinical studies.

Conclusions:

• Targeted liposomes represent a promising approach for enhancing cancer chemotherapy.
• Ligand-directed liposomal drug delivery can improve treatment outcomes by increasing tumor-specific drug concentrations.
• Further research into folate and HER2/neu receptor-targeted liposomes is warranted for clinical translation.